Calibration testing should be done every one
to two years or according to the manufacturer’s suggested timeline. TMDs can
experience a “drift” over time, affecting their accuracy. This testing ensures
the accuracy of the device continues to conform to nationally-accepted
If you need to replace the temperature
monitoring device at your practice or if the cost of calibration testing
outweighs the cost of purchasing a new device, CPP members can access a
discount on LogTag Vaccine Temperature Monitoring Kits. Simply contact the CPP office at mailto:email@example.com
for more information.
As announced at the ACIP meeting last week, supply of the pediatric formulation of Merck’s Recombivax HB will be returning to the private sector. The following vaccine presentations will be available for purchase beginning March 9, 2020:
At this time, the adult formulations of Recombivax HB are
still unavailable. You can keep up on supply updates by visiting the Merck
Supply Status website. Remember, CPP members can access a discount on
Dynavax’s Heplisav-B, a 2-dose hepatitis B vaccine series for adult
patients. To participate in this discount opportunity, contact the CPP
office to request an opt-in form. Once your practice is linked to the
CPP member discount, doses can be purchased
through an authorized distributor
If you have any questions or would like additional information, please contact the CPP Office at 614-722-2145 or your Merck representative.
The immunization schedules for 2020 recently
published by the Center for Disease Control (CDC) four recommendations for
vaccination based on shared clinical
decision-making. These vaccines are:
Meningococcal B (MenB) vaccination
for adolescents and young adults aged 16–23 years
Human papillomavirus (HPV)
vaccination for adults aged 27–45 years
Pneumococcal conjugate vaccination
(PCV13) for adults aged 65 years and older who do not have an
immunocompromising condition, cerebrospinal fluid leak, or cochlear implant
Hepatitis B (HepB) vaccination for
adults age 60 years and older with diabetes mellitus
But what is a shared clinical decision-making
recommendation? According to the CDC, an immunization is given this designation
when it is not indicated for all members of a population. The vaccination may
benefit some members of the age or risk group, but broad vaccination of people
in that group is unlikely to have population-level impacts. For shared clinical
decision-making immunizations, patients and providers should discuss the
potential benefits of vaccination and come to a personalized decision together.
Over the next month, we will examine the
individual immunizations that the ACIP recommends for shared clinical
The HPV vaccination is routinely recommended
for ages 11 or 12 with catch-up recommendations for those not vaccinated on
In June 2019, the ACIP recommended shared
clinical decision-making for HPV vaccination of adults aged 27–45 years. According
to the ACIP
Shared Clinical Decision-Making Recommendations, HPV acquisition generally
occurs soon after first sexual activity. Vaccine effectiveness is lower in
older age groups because of prior infections and lower risk of exposure (for
example, among persons who are in a long-term, mutually monogamous sexual
partnership). The ACIP recommended shared clinical decision-making rather than
catch-up vaccination because most adults in this age group would have no or
minimal benefits from vaccination. However, some individuals who are not already
immune to HPV through vaccination or natural infection (e.g., a previously
unvaccinated person who has never had sex) and who might be at risk for
acquiring a new HPV infection in the future (e.g., plans to have sex with a new
partner in the future) might benefit from vaccination.
A detailed explanation of the ACIP’s
recommendation and considerations for shared clinical decision making regarding
HPV vaccination of adults aged 27 through 45 years can be found on the HPV Updated
Most vaccines have new pricing in 2020.
Here is a summary of the effective dates for all of CPP’s vendor partners:
Merck – effective
Sanofi Pasteur –
Pfizer – effective
Pfizer has announced updated pricing on Trumenba
(and Prevnar 13) that went into effect January 1, 2020. There will be a
discount period when members can place orders for these vaccines at the
pre-increase price until February 26, 2020 (with delivery no
later than February 28, 2020). If you would like electronic or hard copies
of the updated pricing sheet for Trumenba, please contact
the CPP office.
Managing a financially sustainable vaccine program is key to providing the most value to your practice and your patients. This would include checking your invoices to make sure you’re being charged correctly, checking your billing to make sure your billing rates are adjusted to account for the price changes and checking your insurance payments to make sure they have adjusted accordingly. CPP offers several price change management resources that are posted on the CPP Resources Webpage to help members manage through vaccine price changes.
Please contact the CPP office at 614-722-2145 with questions.
For the upcoming 2020-2021 flu season, CPP members will have
two opportunities to save on influenza vaccines:
SANOFI PASTEUR: CPP members who confirm their flu vaccine reservation on VaccineShoppe.com by the March 31, 2020 deadline will receive the discounted member pricing, delivery commitments and returns allowance. Please also note that CPP members can now earn an additional 1% rebate from CPP on all Sanofi Pasteur flu vaccine purchases! To receive these benefits, make sure your Sanofi Pasteur account is linked to the CPP member pricing and confirm your reservation through www.VaccineShoppe.com by the deadline.
ASTRAZENECA: Members who wish to pre-book FluMist doses will have an opportunity to purchase them at a discount, receive a returns allowance and a supply commitment. To receive these benefits, confirm that the DEA # for your practice is linked to CPP by submitting a declaration form and pre-book your FluMist doses through your preferred authorized distributor by January 31, 2020 (Early Pre-Book for a larger discount) or March 31, 2020 (Standard Pre-Book). Declaration forms can be obtained by contacting the CPP office.
All staff in a pediatric practice, including non-clinical
staff, play an important role in supporting parents in their immunization
decisions. Creating a culture of immunization in your office helps promote
complete and timely immunizations. To that end, the CDC and Sanofi Pasteur have
produced helpful resources to aid in building a pro-vaccination culture.
The Immunization Action Coalition and Sanofi Pasteur have
collaborated a project to raise awareness of the low immunization rates for the
meningococcal (MenACWY) vaccination. The project, titled “MenACWY: You’re Not
Done if You Give Just One,” can be found at https://www.give2menacwy.org/ and
contains a wealth of resources for medical practices.
The facts are stark: Meningococcal disease can be deadly,
and survivors can suffer lifelong disabilities from contracting the disease.
Unfortunately, the majority of administration opportunities are missed. Even
during vaccine only visits, 86% of adolescents were not given MenACWY. 1
The recommended administration guidelines are to give the
initial dose at 11-12 years of age and the second dose at 16 years of age. This factsheet
provides important information about recommending and administering MenACWY.
In the upcoming months, CPP will continue posting resources
on increasing adolescent immunization rates and creating a culture of
vaccination in your practice. Subscribe to our blog to stay up to date.
1. Wong CA. Taylor JA, Wright JA, et al. Missed
opportunities for adolescent vaccination, 2006–2011. J Adolesc Health.
On Wednesday, August 28, the CDC will be hosting a webinar
from 1-2pm to assist providers in recommending vaccines and addressing vaccine
Speakers for the webinar include:
Dr. Amanda Cohn, Acting Chief Medical Officer,
Vaccine Policy, Preparedness, Global Health, National Center for Immunization
and Respiratory Diseases, Centers for Disease Control and Prevention
Chanie Sternberg, President & CEO,
Dr. Corinna Manini, Chief Medical Officer,
Dr. Todd Wolynn, CEO, Kids Plus Pediatrics
RefuahHealth is a health center in New York that serves
patients in communities affected by ongoing measles outbreaks. They have worked
to cultivate trust with parents concerning the safety and efficacy of vaccines.
this link for more information and to register. Don’t wait to register for
this timely and relevant information. And stay tuned to the CPP Blog. In the
next few months, we will be posting a series on addressing vaccine hesitancy in
your practice. Subscribe to our blog to stay up to date!
Medical Economics recently published an article highlighting
the benefits of partnering with a group purchasing organization (GPO) or
physician buying group (PBG). Practices can expect savings ranging from 5
percent to 25 percent by joining such a group. Highlights include:
Don’t base your GPO choice on what your hospital
uses. Physician offices have different needs than hospitals. Find a group that
fits your specific needs.
Revisit pricing every year or two and compare
groups. The needs of a practice can change over time, and there is no one size
fits all solution.
Know the difference between a GPO and PBG. GPOs
are membership organizations that offer discounts on most everything involved
in a medical practice such as capital equipment, supplies, and services. PBGs
also offer discounts on supplies and services, but they primarily serve as
vaccine buying groups. Due to their vaccine focus, PBGs are able to provide
Let your vendors do the work of pricing. Put
your top purchased items out for bid to ensure you are getting the best price.
Check if your distributor performs additional
services like stocking and ordering supplies.